We hypothesized that the therapeutic potential of ETS inhibitors targeting EWS-FLI1 (Ewing sarcoma) and ERG-driven tumors (prostate cancer) can be expanded to pediatric leukemia as they are well known to have deregulated ETS activity. This evidence concerns the gene ERG and prostate carcinoma.